We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Journey Medical Corporation | NASDAQ:DERM | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.06 | 1.65% | 3.69 | 3.52 | 5.25 | 3.7299 | 3.52 | 3.63 | 51,784 | 05:00:06 |
From May 2019 to May 2024
By Colin Kellaher
Eli Lilly & Co. (LLY) Friday said it agreed to buy biopharmaceutical company Dermira Inc. (DERM) for $18.75 a share, or about $1.1 billion in cash.
The deal represents a scant 2.2% premium to Thursday's closing price of $18.34 for Dermira, but Eli Lilly said it represents a roughly 86% premium to the 60-day volume-weighted average trading price for the Menlo Park, Calif., company.
Eli Lilly said the acquisition will expand its immunology pipeline with the addition of lebrikizumab, which is being evaluated in a phase 3 study for the treatment of moderate-to-severe atopic dermatitis.
The Indianapolis drug maker said it expects to complete the acquisition, which isn't subject to any financing condition, by the end of the first quarter.
Dermira shares rose 0.9% to $18.51 in light premarket trading Friday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 10, 2020 06:58 ET (11:58 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Journey Medical Chart |
1 Month Journey Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
